The entry of Supect’s primary treatment is drawing near

‘Supect(ladotinib),’ a domestic new drug for chronic myeloid leukemia(CML), will soon become a primary treatment.

According to the industry concerned on the 27^th, the indication expansion application which was turned in by Ilyang Pharmaceutical last July has been made and the Ministry of Food and Drug Safety is currently having the last moment to review it. At the earliest, it will be approved...